1 / 4

Industry-Payor Agreements for Pharmaceuticals Survey results

Industry-Payor Agreements for Pharmaceuticals Survey results. Eddy Nason, IOG Director April 3 rd 2011. Survey purpose and responses. The survey was designed to provide input on the main values and barriers around “innovative” agreements.

hinto
Download Presentation

Industry-Payor Agreements for Pharmaceuticals Survey results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Industry-Payor Agreements for PharmaceuticalsSurvey results Eddy Nason, IOG Director April 3rd 2011

  2. Survey purpose and responses • The survey was designed to provide input on the main values and barriers around “innovative” agreements. • Respondents were from a wide variety of stakeholder groups • Respondents mainly from Canada, but some international. Primary Sector Jurisdiction Pharma Canada Govm’t N.America Academe EU HTA Australasia Other Other Industry-Payor Agreements for Pharmaceuticals: Survey Results

  3. What value is brought by these agreements? • Increased patient access • Managing real world patterns of use of drugs • Addressing effectiveness and cost-effectiveness were seen as areas where innovative agreements can add value Pharma Govm’t Academe HTA Industry-Payor Agreements for Pharmaceuticals: Survey Results

  4. What are the main barriers and facilitators for agreements? • Main barriers: • Capacity or expertise in government • Process of monitoring the performance of agreements (organizational capacity and structure to monitor) • Ability to gather information on performance to assess objectives of the agreement • Main facilitators: • Willingness in industry • To a lesser extent: • Willingness in government • Expertise in industry Barrier Barriers/Facilitators Facilitator Neutral Industry-Payor Agreements for Pharmaceuticals: Survey Results

More Related